Objective: To evaluate whether main tumor resection improves survival compared with pleural biopsy alone in patients with lung adenocarcinoma with intraoperatively diagnosed pleural seeding.
Perspective
Main tumor and visible pleural nodule resection followed by multimodality adjuvant therapy achieved better survival than pleural biopsy alone in patients with lung adenocarcinoma intraoperatively diagnosed pleural seeding. There was no significant survival difference between sublobar resection and lobectomy as the main tumor resection. Randomized trials are needed to confirm these results.
See Editorial Commentaries pages 1250 and 1252.
See Editorial page 1207.
Lung cancer is the leading cause of cancer deaths worldwide. 1 Surgical resection is the treatment of choice for early-stage non-small cell lung cancer (NSCLC), whereas systemic chemotherapy is the standard of care for patients with stage IV disease. 2 In the 7th edition of the American Joint Committee on Cancer's TNM staging system for lung cancer, pleural seeding and malignant pleural effusion were reclassified from T4 to M1a. 3 The 2017 8th edition of this staging system maintained the classification. 4 Patients with NSCLC with M1a metastases have poor outcomes, with a median survival time (MST) of 11.5 months, and M1a metastasis is generally considered a contraindication for curative main tumor resection. 5 Patients with M1a metastases present with a range of disease severity, from minimal disease with only a single small pleural seeding and no malignant pleural effusion to advanced disease with multiple large pleural nodules and massive malignant pleural effusion. 6 Occasionally, thoracic surgeons detect unexpected pleural nodules intraoperatively in patients in clinical stage M0 with what was presumed to be operable disease. Intraoperatively diagnosed pleural seeding is usually localized and small, evading detection on preoperative imaging. If pleural seeding is detected unexpectedly during surgery and confirmed by frozen section, the current consensus favors open-close surgery followed by chemotherapy or targeted therapy for stage IV disease. 7 Recently, improved multimodality treatment options have become available for stage IV NSCLC, including new chemotherapy regimens, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), anaplastic lymphoma kinase (ALK) TKIs, and immunotherapy. 8, 9 Photodynamic therapy and hyperthermic intrapleural chemotherapy may represent beneficial alternatives for patients with malignant pleural disease. 10 In addition, developments in minimally invasive surgery and postoperative care have improved surgical outcomes and decreased surgery-related morbidity. 11, 12 Several recent studies have reported the use of curative surgery in NSCLC with intraoperatively diagnosed pleural seeding, showing a survival benefit of main tumor resection. [13] [14] [15] [16] [17] [18] However, the long-term outcomes of these patients are not known, and there is no consensus regarding the appropriate surgical approach. We thus evaluated whether resection of the main tumor improved survival compared with pleural biopsy alone in patients with intraoperatively diagnosed pleural seeding. Given that adenocarcinoma is the most common histology in patients with NSCLC with pleural carcinomatosis, with a reported prevalence of 64% to 87.2%, [13] [14] [15] [16] [17] [18] [19] we evaluated only patients with histologically proven adenocarcinoma.
METHODS Patients
We retrospectively reviewed charts from 4591 consecutive patients with lung cancer undergoing surgical resection between January 2006 and December 2014. Data were obtained from a prospectively collected database at the National Taiwan University Hospital. The 4591 patients included 55 (1.2%) with NSCLC with pleural seeding diagnosed unexpectedly during surgery. We excluded 12 patients, including 7 with multiple lung tumors, 2 with a histological type other than adenocarcinoma (lymphoepithelioma-like carcinoma), 1 with clinical N3 staging before surgery, and 2 lost to postoperative follow-up. Finally, 43 patients with a single lung adenocarcinoma and pleural seeding diagnosed unexpectedly during surgery were included. Main tumor and visible pleural nodule resection was performed in 30 patients (tumor resection group). The remaining 13 patients underwent pleural nodule biopsy alone (open-close group). Clinicopathological parameters were collected from the lung cancer database. Clinical Tand N stages were classified according to the American Joint Committee on Cancer's 8th TNM Classification for Lung and Pleural Tumors. 4 The National Taiwan University Hospital Research Ethics Committee approved the study (project approval no. 201601006RINC; approval date, February 16, 2016) and waived informed consent for this retrospective study.
Preoperative staging procedures included chest radiography, blood chemistry analysis and serum carcinoembryonic antigen measurement, brain computed tomography (CT) or magnetic resonance imaging (MRI), chest and abdominal CT, positron emission tomography (PET) scanning or bone scanning, and pulmonary function tests. All imaging studies were performed within 2 months preoperatively. Chest ultrasonography for thoracentesis was performed routinely in patients with preoperatively noted pleural effusion, and patients with preoperatively confirmed malignant pleural effusion (M1a) were excluded. Neither image-detected pleural seeding nor distant metastases were noted preoperatively in the final study population. All tumors were preoperatively staged as resectable in the 43 study patients.
Patient Follow-up
Patients were regularly monitored in the outpatient clinic with physical examination, serum carcinoembryonic antigen measurement, brain CT, and chest CT every 3 months for the first 2 years. Thereafter, patients were regularly monitored with similar examinations every 3 to 6 months according to the attending physician's instructions.
Bronchoscopy, brain CT, brain MRI, PET, lymph node biopsy, chest ultrasound, and other tests were performed whenever any symptoms or signs of tumor recurrence were noted. Local progression was defined as main tumor enlargement in the open-close group and as lesion recurrence at the resection margin in the tumor resection group. Regional progression was defined as malignant pleural effusion or pleural nodules, new lung lesions, or ipsilateral lymph node recurrence. Lymph node recurrence was defined 
Statistical Analysis
Patient clinicopathological characteristics, surgical procedures, surgical approaches, and patient outcomes were compared between groups using Fisher's exact test for categorical variables (frequency and percentage) and the Wilcoxon rank-sum test for continuous variables (mean, standard deviation, and range). Progression-free survival (PFS) was defined as the time from surgery to any disease progression. Overall survival (OS) was defined as the time from surgery to death or the last follow-up. PFS and OS were tested using Kaplan-Meier survival plots and analyzed with log-rank tests. Prognostic factors for PFS and OS were analyzed by univariate analysis, and comparisons were made using log-rank tests. Subsequently, a multivariable Cox proportional hazards model was fitted and adjusted for several parameters, including tumor size, clinical N stage, malignant pleural effusion, degree of pleural nodule dissemination, preoperative PET, and EGFR mutation status. Results are presented as hazard ratio and 95% confidence intervals (CIs). All tests were 2-sided, and a P value < .05 was considered to indicate statistical significance. Data were analyzed using SPSS version 23 (IBM, Armonk, NY) and Stata 13 (StataCorp, College Station, Tex).
RESULTS

Patient Demographics and Clinicopathological Characteristics
We evaluated 43 patients with single lung adenocarcinoma and pleural seeding diagnosed unexpectedly intraoperatively. The mean duration of follow-up was 28.0 months (range, 4-118 months). The mean age was 58 years (range, 29-80 years), and 74.4% of patients were nonsmokers (32 of 43). Females accounted for 62.8% of the study patients (27 of 43). Twenty-three patients (53.5%; 23 of 43) were in clinical stage T1, and 30 patients (69.8%; 30 of 43) were in clinical stage N0. An EGFR mutation was noted in 58.1% of patients. The clinical T stage was higher in the open-close group than in the tumor resection group (P ¼ .02). There were no other significant differences between the 2 groups. Other demographic data, clinicopathological characteristics, preoperative staging workup, and neoadjuvant and adjuvant treatments of the entire study group are presented in Table 1 .
Operative and Perioperative Results
All patients initially underwent video-assisted thoracoscopic surgery (VATS). Pleural nodules were found unexpectedly ( Figure 1 ) and were pathologically confirmed by intraoperative frozen sections to be pleural seeding. The degree of pleural metastasis was defined as localized if 3 or fewer pleural nodules were found. Otherwise, the degree of pleural metastasis was defined as diffused. 13 Pleural metastasis was localized and diffused in 4 and 39 patients, respectively. Malignant pleural effusion was present in 8 patients (18.6%) ( Table 2) .
Following the confirmation of pleural seeding, surgery was either terminated (open-close group; n ¼ 13) or preceded to main tumor and visible pleural nodule resection (tumor resection group; n ¼ 30). The choice of main tumor resection or pleural biopsy alone was at the surgeon's discretion. In the tumor resection group, patients had a significantly lower clinical T stage (P ¼ .02) and tended to have localized pleural metastasis (P ¼ .30; 13.3% vs 0%). To completely remove grossly visible pleural metastases located in the same area with adequate resection margin, pleurectomy was performed in 14 of the 30 patients (46.7%) in the tumor resection group ( Figure E1 ). The other 16 patients underwent removal or ablation of visible pleural nodules without pleurectomy. All patients underwent pleural biopsy alone for diagnostic purposes in the pleural biopsy group.
Seventeen of the 30 patients in the tumor resection group underwent segmentectomy (n ¼ 1) or wedge resection (n ¼ 16). The remaining 13 underwent lobectomy for main tumor removal. Systematic lymph node dissection was performed in all patients who underwent anatomic resection, including lobectomy (n ¼ 13) and segmentectomy (n ¼ 1). Mediastinal lymph node dissection was performed in 9 of the 16 patients who underwent wedge resection (56.3%). The remaining patients underwent resection of the main tumor and visible pleural nodules only. Operative times were longer in the tumor resection group compared with the open-close group (mean, 141.8 vs 80.3 minutes; P <.001). There were no other statistically significant between-group differences in perioperative outcomes, including operative bleeding, postoperative hospital stay, morbidity, and mortality (Table 2) . In the open-close group, 5 of 13 patients (38.5%) received a first course of adjuvant chemotherapy while hospitalized. In contrast, all patients in the tumor resection group received adjuvant treatment after discharge. Therefore, the mean hospital stay was longer in the open-close group than in the tumor resection group (8.2 vs 6.9 days). Three complications occurred overall. One patient from the open-close group experienced postoperative bleeding. Two patients from the tumor resection group had vocal cord palsy, with prolonged ventilator support and intraoperative bleeding, respectively. Only the patient who underwent lobectomy and experienced massive intraoperative bleeding underwent conversion from VATS to traditional thoracotomy for hemostasis. The remaining surgeries were performed with VATS.
Neoadjuvant and Adjuvant Treatment
Among the 43 patients, 9 (20.9%) underwent neoadjuvant treatment, including 8 who received chemotherapy and 1 who received EGFR TKI therapy. One patient in the open-close group and 7 patients in the tumor resection group received platinum-based neoadjuvant chemotherapy. The remaining patient in the tumor resection group received neoadjuvant EGFR TKI therapy (Table 1) . Two patients underwent surgery before January 2008, and both received platinum-based chemotherapy as first-line adjuvant treatment. Tumor specimens (n ¼ 41) obtained after January 2008 were sent for EGFR mutation analysis postoperatively. EGFR TKIs, including gefitinib (Iressa) or erlotinib (Tarceva), were prescribed for all patients with positive EGFR mutations and as an alternative second-line treatment for patients without ERGR mutations. Platinum-based chemotherapy was prescribed within 1 month Figure E2 ).
Disease Progression Patterns
Tumor progression was noted in 24 patients. Seventeen experienced local progression, 19 experienced regional progression, and 16 had distant metastases. Tumor progression was diagnosed by CT in 41.7% of these patients, by biopsy (thoracentesis of malignant pleural effusion, needle biopsy, or surgical biopsy) in 25%, by brain MRI in 20.8%, and by PET in 12.5%. Distant metastatic sites included the contralateral lung (n ¼ 7), brain (n ¼ 7), bone (n ¼ 3), skin (n ¼ 2), and adrenal gland (n ¼ 1). Three of the 16 patients (18.8%) with distant metastases had more than 1 site of recurrence at diagnosis.
We analyzed the disease progression patterns to clarify the differences in survival between the tumor resection and the open-close groups. As shown in Figure 3 , A and B, compared with the open-close group, the tumor resection group had a significantly greater local progression-free duration (3-year probability, 67.8% vs 35.9%; P ¼ .002) and regional progression-free duration (3-year probability, 61.5% vs 20.8%; P ¼ .026). There was no significant between-group difference in the time from surgery to the detection of distant metastasis (3-year probability, 75.7% vs 22.7%; P ¼ .083), but the time to metastasis detection tended to be longer in the tumor resection group (Figure 3, C) .
DISCUSSION
Pleural seeding generally conveys a poor prognosis in patients with NSCLC. [2] [3] [4] [5] Based on the results of the new International Association for the Study of Lung Cancer's lung cancer database for 1999 to 2010, the MST of M1a patients was 11.5 months. 5 However, our results show that in both the tumor resection and open-close groups, patients with pleural seeding first detected at surgery had a better prognosis than patients with clinically diagnosed pleural seeding, with a 3-year OS of 69.2%. In a multicenter study of the Japanese Clinical Oncology Group in 2000, Ichinose and colleagues 20 first reported an unexpectedly good prognosis for patients with resected NSCLC with carcinomatous pleuritis of minimal disease, with 3-year and 5-year OS rates of 31.8% and 22.8%, respectively. This was the largest study reported to date, with 227 patients, 100 of whom underwent main tumor resection. In 2002, another study showed the opposite results, with no survival benefit of main tumor resection in patients with NSCLC with minor malignant pleural effusion. 21 High-resolution CT and PET detects most cases of pleural involvement or malignant pleural effusion during clinical staging. False-negative cases, such as our study patients, are in a relatively early stage of pleural metastasis. Along with postoperative chemotherapy and targeted therapy, primary tumor control in patients with unexpected and limited pleural seeding could be beneficial. In the most recent decade, several reports have described patients with NSCLC undergoing main tumor resection, despite intraoperatively diagnosed pleural seeding. [13] [14] [15] [16] [17] [18] 22 These reports show favorable outcomes, similar to our results, with MSTs ranging from 15 to 52 months and 5-year OSs ranging from 16.3% to 42.7%. [13] [14] [15] [16] [17] [18] These studies are summarized in Table 5 . [13] [14] [15] [16] [17] [18] 21, 22 In addition, a 2016 metaanalysis identified primary tumor resection as a beneficial prognostic factor in patients with NSCLC with intraoperatively diagnosed malignant pleural disease. 23 Our findings demonstrate superior PFS and OS rates in the tumor resection group compared with the open-close group. Ren and colleagues 13 reported that main tumor resection conveyed survival benefits superior to those for pleural biopsy alone (3-year OS, 45.8% vs 11.8%). Yun and colleagues 14 also found that main tumor excision increased long-term survival in patients with NSCLC with localized pleural seeding first detected intraoperatively. Although the surgical time was significantly longer in the tumor resection group than in the open-close group, main tumor resection did not increase morbidity or mortality (Video 1). 13, 14 Lobectomy remains the standard treatment for earlystage NSCLC. 24, 25 Sublobar resection is generally considered to have inferior survival to that for lobectomy, and is considered for patients with major comorbidities contraindicated for lobectomy. 25, 26 Recent studies have shown that survival following wedge resection might be superior to that for stereotactic body radiotherapy for early-stage NSCLC. 27, 28 Of the 30 patients in our study's tumor resection group, 13 underwent lobectomy and 17 underwent sublobar resection. In the 13 patients with lobectomy, tumors were located centrally and could not be resected by sublobar resection. There were no significant between-group differences in OS and PFS. Several previous studies have shown similar results, with no significant survival differences between extensive resection (pneumonectomy, bilobectomy, and lobectomy) and limited resection (wedge resection and segmentectomy). 15, 16, 18 Okamoto and colleagues 17 reported much worse outcomes in patients who underwent pneumonectomy compared with those who underwent more limited EGFR, Epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; VATS, video assisted thoracotomy; MST, median survival time; N/A, not available. *The study analyzed NSCLC patients with ipsilateral malignant pleural effusion from the Surveillance, Epidemiology, and End Results (SEER) registry patients. yThe study analyzed NSCLC patients with M1a disease who underwent surgical resection, including preoperatively diagnosed and intraoperatively diagnosed M1a disease (pleura/pericardial nodules, pleura/pericardial effusion, contra/bilateral lung nodules). zThe study analyzed NSCLC patients with malignant minor pleural effusion (<300 mL), including 16 patients of pleural dissemination that was diagnosed during surgery. The median survival time and 5-year overall survival were 13 months and 9% for complete tumor resection group (n ¼ 11); 34 months and 10% for incomplete tumor resection group (n ¼ 14); and 17 months and 0% for biopsy alone group (n ¼ 18). resection (P ¼ .013). For M1a patients, main tumor resection may serve as a debulking surgery before multimodality adjuvant therapy for tumor cell cytoreduction, rather than curative surgery. Therefore, the treatment goal would be main tumor resection rather than extensive resection of uninvolved lung parenchyma. Several studies have reported numerous prognostic factors for PFS and OS, including adenocarcinoma histology, absence of pleural effusion, nonsmoker, administration of adjuvant therapy, and N0-1 lymph node staging. [13] [14] [15] [16] [17] [18] In this study, there was no significant survival difference between N0 and N1-2 lymph node staging. We hypothesized that carcinomatous pleuritis without lymph node metastasis is related to visceral pleural invasion and local tumor extension. 29 Although lymph node metastasis is a well-established prognostic factor, the degree of pleural nodule dissemination may play a more important role in the prognosis of patients with carcinomatous pleuritis. However, there remains a discrepancy in N status between clinical and pathological N stage, which may lead to bias in survival analyses. 16 Although the results are not identical for these studies, the reported prognostic factors may help surgeons select patients for curative surgery and more accurately predict surgical outcomes.
Our results showed better surgical outcomes than those reported previously. Actually, more recent studies have shown a trend toward better survival than reported in earlier studies (Table 5) , [13] [14] [15] [16] [17] [18] which may be related to improvements in multimodality lung cancer treatment and surgical techniques. Twenty-nine patients (67.4%) in this study received EGFR TKI treatment. In addition, 4 patients (9.3%) received ALK TKI, and 1 patient underwent a second surgery for radical pleurectomy and photodynamic therapy. Improvements in adjuvant therapies may further improve surgical outcomes for patients with unexpected M1a disease. The popularity of postoperative therapies, which are covered by the National Health Insurance of Taiwan, also accounts for the improved OS of both groups compared with that previously reported for M1a patients. 30 Accessibility of the main tumor and the surgery's simplicity also affect decision making when surgeons face intraoperatively diagnosed pleural seeding. In our study, all patients underwent thoracoscopic surgery, and only 1 patient required conversion to thoracotomy for hemostasis. Advances in minimally invasive surgery for treating lung cancer, including single-port VATS, nonintubated VATS, and robotic-assisted thoracoscopic surgery with accurate intraoperative tumor localization, may minimize surgery-related morbidity and mortality, shorten hospital stays, and improve surgical outcomes. 11, 12, [31] [32] [33] [34] [35] We acknowledge several limitations of this study. As a retrospective, single-institution study, time-trend bias and patient-selection bias were inevitable. We selected the study duration to incorporate most of the EGFR TKI era and to minimize the influence of the introduction of targeted therapy. Compared with previous studies, [13] [14] [15] [16] [17] [18] our relatively short study period should help minimize time-trend biases. Patient selection bias existed in the comparison of these 2 groups. A higher T stage and more diffused pleural nodules may be associated with a surgeon's tendency to select openclose procedures. The study cohort was exclusively Asian, with a high proportion of nonsmoking women with EGFR mutations, which are independently favorable risk factors. These factors may have contributed to the excellent survival in this series, and thus extrapolation to other NSCLC populations should be done with caution. Our study results should be validated in other areas of the world. The small number of cases is another limitation. Owing to the low incidence of unexpected pleural seeding found intraoperatively, a larger multi-institutional randomized study is needed to validate our results.
CONCLUSIONS
Based on our results and current evidence, main tumor and visible pleural nodule resection followed by multimodality adjuvant therapy may achieve better OS and PFS than pleural biopsy alone in patients with lung adenocarcinoma with intraoperatively diagnosed pleural seeding. The survival benefit may be related to patients having smaller tumors and more limited pleural disease. More extensive surgeries do not suggest a survival benefit. Our results suggest that patients may undergo sublobar resection of the main tumor when feasible. Because this study was retrospective with a small number of patients, further prospective randomized trials are warranted to validate our results.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/media/ 17AM/2017-05-03/RM312/05-03-17_Room312_0914_Lin. mp4.
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Discussion
Dr Benny Weksler (Memphis, Tenn). Dr Lin, congratulations on an excellent presentation and thank you for sending me the manuscript way ahead of time. You present survival data for 43 lung cancer patients with adenocarcinoma, 30 who underwent resection of primary tumors and pleural metastases and 13 who did not have any resection, and you conclude that survival is improved with resection of pleural implant. It is certainly a provocative study that challenges our current management of these patients.
Besides the small numbers, I have significant concerns regarding selection bias in your study. It would be logical FIGURE E1. Pleurectomy was performed after the surgeon regarded the pleural metastasis as completely resectable. A, Thoracoscopic view of the right upper lobe main tumor and pleural metastasis (arrows). Although there were more than 3 pleural nodules and the patient was thus considered to have diffused pleural metastasis, these grossly visible nodules were located in the same area and could be completely resectable. B, Parietal pleura after video-assisted thoracoscopic surgery pleurectomy. 
